Lakewood-Amedex Biotherapeutics Inc. (LABT) AI Stock Summary

Snapshot

Lakewood-Amedex is a clinical-stage biotech with no products on the market and no revenue. It lost $3.8M in FY 2025 and burned $1.9M in free cash flow, leaving just $236K in cash against $1.7M of debt. At that burn rate, the cash runway is about 9.1 months. The company just did a 1-for-10 reverse split in June 2026 and shares outstanding nearly doubled YoY, and the stock trades near its 52-week low.

What's Happening Right Now

• Sun 23rd Aug '26 · Proxy filing: A preliminary proxy for the September 22, 2026 annual meeting seeks to raise authorized shares from 12.5 million to 100 million and pre-authorize another reverse split (up to 1-for-20) to stay compliant with Nasdaq listing rules.
• Wed 22nd Jul '26 · Clinical data: The company highlighted resistance data showing Nu-3 has a high barrier to resistance, tying the release to a federal antibiotic-resistance action plan.
• Wed 15th Jul '26 · Clinical update: Lakewood-Amedex announced preclinical safety data supporting dose selection (2%, 5%, 10% gel) for its upcoming Phase 2a trial of Nu-3 gel in infected diabetic foot ulcers.
• Mon 22nd Jun '26 · Patent: Lakewood-Amedex secured a new Australian composition-of-matter patent covering additional Bisphosphocin compounds being explored for UTIs and pulmonary infections.
• Mon 22nd Jun '26 · Reverse split: On June 22, 2026, the company completed a 1-for-10 reverse stock split, cutting shares outstanding from about 17.5 million to about 1.75 million.

Ownership

Institutions hold 0.0% of shares, and insiders hold 5.1%.

Bottom Line

This is a pre-revenue biotech running on a thin cash cushion, with less than a year of runway at current spending and share count nearly doubling in the past year. The June 2026 reverse split and a proxy proposal to authorize yet another one signal a company that has been under sustained pressure to stay listed. The Nu-3 clinical progress and new patent are real developments, but the financial picture is strained and shareholders have already been diluted heavily.